GSK Joins Race To Tackle Coronavirus
Teams Up With CEPI
Executive Summary
The pharma major is providing its adjuvant system, designed to enhance the body’s immune response, to help the Coalition for Epidemic Preparedness Innovations' efforts to accelerate the creation of a vaccine for the coronavirus strain that broke out in China and has spread to 24 countries.
You may also be interested in...
Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.
AZ and GSK Dip Into Diagnostics To Support COVID-19 UK Tests
The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.
Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine
Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.